tiprankstipranks
Trending News
More News >
Gain Therapeutics reports preclinical data n GT-02287
PremiumThe FlyGain Therapeutics reports preclinical data n GT-02287
1M ago
Promising Developments in Gain Therapeutics’ GT-02287 Drive Buy Rating
Premium
Ratings
Promising Developments in Gain Therapeutics’ GT-02287 Drive Buy Rating
2M ago
Promising Developments in Gain Therapeutics’ Parkinson’s Treatment Justify Buy Rating
Premium
Ratings
Promising Developments in Gain Therapeutics’ Parkinson’s Treatment Justify Buy Rating
2M ago
Gain Therapeutics reports FY24 EPS (89c), consensus ($1.00)
PremiumThe FlyGain Therapeutics reports FY24 EPS (89c), consensus ($1.00)
3M ago
Gain Therapeutics reports Q4 EPS (89c), consensus ($1.00)
Premium
The Fly
Gain Therapeutics reports Q4 EPS (89c), consensus ($1.00)
3M ago
Buy Rating for Gain Therapeutics: Innovative AI-Driven Approach and Promising Parkinson’s Treatment
Premium
Ratings
Buy Rating for Gain Therapeutics: Innovative AI-Driven Approach and Promising Parkinson’s Treatment
3M ago
Gain Therapeutics initiated with an Outperform at Scotiabank
PremiumThe FlyGain Therapeutics initiated with an Outperform at Scotiabank
3M ago
Gain Therapeutics Advances GT-02287 in Parkinson’s Trials
Premium
Company Announcements
Gain Therapeutics Advances GT-02287 in Parkinson’s Trials
4M ago
Gain Therapeutics CEO says 2025 ‘poised to be another pivotal year’
Premium
The Fly
Gain Therapeutics CEO says 2025 ‘poised to be another pivotal year’
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100